HLX10 plus chemotherapy before and after breast cancer surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether a drug called HLX10, given with chemotherapy before surgery (neoadjuvant) and alone after surgery (adjuvant), works better and is safe for people with triple-negative breast cancer. It’s meant for newly diagnosed patients who have not had prior cancer treatment for this breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed triple-negative breast cancer (no HER2, ER, or progesterone receptors).
- Your cancer stage is one of several specific early-to-locally advanced stages with no distant spread to other organs.
- You can have trial treatment because your major organs (like heart, liver, and kidneys) are working well.
- You can use contraception during the study and follow pregnancy prevention rules.
- You have not had chemotherapy, targeted therapy, or radiation for this breast cancer within the past 12 months.
- You have no major allergy to monoclonal antibodies or the trial medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This trial tests a new drug, HLX43, by itself or combined with other immunotherapy drugs for people with advanced triple-negative breast cancer (TNBC) that has spread or cannot be removed by surgery. The goal is to see if these treatments can shrink tumors or slow cancer growth.
This trial tests a new drug called QL1706 combined with chemotherapy given before surgery for people with early-stage, high-risk breast cancer that is estrogen receptor positive (ER+) and HER2 negative. The goal is to see if this combination can shrink tumors more effectively before surgery.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.